WO2002020615A3 - Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders - Google Patents

Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders Download PDF

Info

Publication number
WO2002020615A3
WO2002020615A3 PCT/EP2001/010433 EP0110433W WO0220615A3 WO 2002020615 A3 WO2002020615 A3 WO 2002020615A3 EP 0110433 W EP0110433 W EP 0110433W WO 0220615 A3 WO0220615 A3 WO 0220615A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine
antibody
constructs
pharmaceutical composition
hosts
Prior art date
Application number
PCT/EP2001/010433
Other languages
French (fr)
Other versions
WO2002020615A2 (en
Inventor
Matthias Mack
Detlef Schloendorff
Michael Spring
Original Assignee
Micromet Ag
Matthias Mack
Detlef Schloendorff
Michael Spring
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/948,004 external-priority patent/US6723538B2/en
Application filed by Micromet Ag, Matthias Mack, Detlef Schloendorff, Michael Spring filed Critical Micromet Ag
Priority to JP2002525234A priority Critical patent/JP2004508036A/en
Priority to CA002421842A priority patent/CA2421842A1/en
Priority to HU0300942A priority patent/HUP0300942A2/en
Priority to EP01980364A priority patent/EP1317284A2/en
Priority to AU2002212225A priority patent/AU2002212225A1/en
Publication of WO2002020615A2 publication Critical patent/WO2002020615A2/en
Publication of WO2002020615A3 publication Critical patent/WO2002020615A3/en
Priority to NO20031070A priority patent/NO20031070L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)

Abstract

The present invention relates to the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition for the elimination of cells which are latently infected with a primate immunodeficiency virus. In addition, the present invention provides for the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition of the treatment, prevention and/or alleviation of inflammatory renal diseases, inflammatory bowel diseases, multiple sclerosis, skin diseases, diabetes or transplant rejection. Furthermore, the invention relates to antibody constructs and/or chemokine constructs wherein said antibody construct comprises a binding site of chemokine receptor 5 and a binding site for CD3 and wherein said chemokine construct comprises RANTES and a toxin. The invention also describes polynucleotides encoding said antibody- or chemokine constructs, and vectors and hosts comprising said nucleic acid molecules. Additionally, the present invention relates to compositions comprising said antibody constructs, chemokine constructs, polynucleotides, vectors and/or hosts. Preferably said composition is a pharmaceutical composition. Described is also the use of antibody constructs, the chemokine constructs, the polynucleotides, the hosts and/or the vectors of the preparation of a pharmaceutical composition and methods for treating, preventing and/or alleviating an immunological disorder or for eliminating latently infected cells, wherein said cells are infected with a primate immunodeficiency virus, like HIV-1. Furthermore, the invention provides for a kit comprising the compounds of the invention.
PCT/EP2001/010433 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders WO2002020615A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002525234A JP2004508036A (en) 2000-09-08 2001-09-10 Antibodies and / or chemokine constructs and their use in immune disorders
CA002421842A CA2421842A1 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
HU0300942A HUP0300942A2 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs and their use in immunological disorders
EP01980364A EP1317284A2 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
AU2002212225A AU2002212225A1 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
NO20031070A NO20031070L (en) 2000-09-08 2003-03-07 Antibody and / or chemokine constructs and their use in immunological disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00119694 2000-09-08
EP00119694.8 2000-09-08
US09/948,004 2001-09-05
US09/948,004 US6723538B2 (en) 1999-03-11 2001-09-05 Bispecific antibody and chemokine receptor constructs

Publications (2)

Publication Number Publication Date
WO2002020615A2 WO2002020615A2 (en) 2002-03-14
WO2002020615A3 true WO2002020615A3 (en) 2002-07-25

Family

ID=32842663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010433 WO2002020615A2 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders

Country Status (10)

Country Link
EP (1) EP1317284A2 (en)
JP (1) JP2004508036A (en)
AU (1) AU2002212225A1 (en)
CA (1) CA2421842A1 (en)
HU (1) HUP0300942A2 (en)
NO (1) NO20031070L (en)
PL (1) PL366062A1 (en)
RU (1) RU2252786C2 (en)
WO (1) WO2002020615A2 (en)
ZA (1) ZA200301890B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291035T1 (en) * 2001-12-21 2005-04-15 Micromet Ag SINGLE AND DUAL ANTI-CD4-RANTES CHEMOKINE/CYTOKINE CONSTRUCTS
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
WO2007041364A2 (en) * 2005-09-30 2007-04-12 Government Of The United States Of America, As Represented By The Secretary Conjugates for modulating the immune tolerance
EA021255B1 (en) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Antagonistic human light-specific human monoclonal antibodies
PE20081785A1 (en) 2007-02-19 2009-01-12 Novartis Ag CYCLOHEXYL-AMIDE DERIVATIVES OF ARYL CARBOXYL ACID
NO2195023T3 (en) 2007-08-29 2018-08-04
WO2012000906A1 (en) * 2010-06-28 2012-01-05 Universitätsklinikum Freiburg Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer
RU2663123C2 (en) 2010-11-30 2018-08-01 Чугаи Сейяку Кабусики Кайся Cytotoxicity-inducing therapeutic agent
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
BR112016026299A2 (en) 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha The T-lymph cell redirection antigen joint molecule to the cell which has an immunosuppressive function
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017210749A1 (en) * 2016-06-10 2017-12-14 Adelaide Research & Innovation Pty Ltd Methods and products for treating autoimmune diseases
CN109970856B (en) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 anti-LAG-3 antibodies and uses thereof
WO2021146272A1 (en) * 2020-01-13 2021-07-22 The Regents Of The University Of California Methods for treating viral infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004926A2 (en) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
WO2000053633A2 (en) * 1999-03-11 2000-09-14 Micromet Ag Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004926A2 (en) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
WO2000053633A2 (en) * 1999-03-11 2000-09-14 Micromet Ag Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
H. BRUHL ET AL.: "Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV.", THE JOURNAL OF IMMUNOLOGY, vol. 166, no. 4, 15 February 2001 (2001-02-15), Baltimore, MD, USA, pages 2420 - 2426, XP002197003 *
L. WU ET AL.: "Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 8, 20 October 1997 (1997-10-20), Tokyo, Japan, pages 1373 - 1381, XP002060734 *
M. MACK ET AL.: "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 92, 18 July 1995 (1995-07-18), Washington, DC, USA, pages 7021 - 7025, XP000566333 *
M. MACK ET AL.: "Aminooxypentane-RANTES induces CCR5 internalization but inhibits recyling: a novel inhibitory mechanism of HIV infection.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 8, 20 April 1998 (1998-04-20), tokyo, japan, pages 1215 - 1224, XP000916445 *
M. MACK ET AL.: "Depletion of CCR5+ cells with bispecific antibodies and chemokine-toxins: A new strategy to treat inflammatory renal diseases.", KIDNEY & BLOOD PRESSURE RESEARCH, vol. 23, no. 3-5, 2000, Basel, Switzerland, pages 242, XP001073509 *

Also Published As

Publication number Publication date
NO20031070D0 (en) 2003-03-07
CA2421842A1 (en) 2002-03-14
EP1317284A2 (en) 2003-06-11
NO20031070L (en) 2003-05-06
HUP0300942A2 (en) 2003-09-29
RU2252786C2 (en) 2005-05-27
WO2002020615A2 (en) 2002-03-14
PL366062A1 (en) 2005-01-24
JP2004508036A (en) 2004-03-18
ZA200301890B (en) 2004-03-16
AU2002212225A1 (en) 2002-03-22

Similar Documents

Publication Publication Date Title
WO2002020615A3 (en) Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
WO1997017446A3 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
RU2007108067A (en) ANTAGONISTIC ANTIBODIES TO IL-17
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
WO2001032711A3 (en) Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
JP2015501134A5 (en)
IL212686A0 (en) Oligodendrocyte binding human monoclonal igm antibodies and compositions and uses thereof
HK1029123A1 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
NO20070347L (en) Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic applications
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
JP2004502421A5 (en)
JP2006519228A5 (en) How to use an antibody to immunotolerize primates against antigens
RU2386639C2 (en) Linking molecules having therapeutic activity
DE69333627T2 (en) RECOMBINANT ANTI-HIV ANTIBODY AND ITS MANUFACTURE
RU2014114015A (en) METHODS FOR TREATING INFLAMMATORY DISORDERS USING ANTIBODIES AGAINST M-CSF
TW201946932A (en) BTLA agonist antibodies and uses thereof
RU2003108885A (en) STRUCTURES OF ANTIBODIES AND CHEMOKINES AND THEIR APPLICATION IN IMMUNOLOGICAL DISORDERS
KR102561555B1 (en) Antibodies for treatment of hepatitis B infection and related diseases
JP2006511620A5 (en)
Soma et al. Immunoglobulin γ3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia
WO2001068568A3 (en) Il-8 receptor antagonists
WO2002026781A3 (en) Ige receptor antagonists
WO2001068569A3 (en) Il-8 receptor antagonists
WO2005103702A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
WO2005072380A3 (en) Membrane attack complexes associated with circulating immune complexes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003/01890

Country of ref document: ZA

Ref document number: 2421842

Country of ref document: CA

Ref document number: 200301890

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002525234

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001980364

Country of ref document: EP

ENP Entry into the national phase

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2003108885

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001980364

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642